LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Remotely Controlled Miniature Biological Robots Could Be Used for MIS and Detection of Disease Biomarkers

By LabMedica International staff writers
Posted on 23 Jan 2023
Print article
Image: The eBiobots are the first wireless bio-hybrid machines, combining biological tissue, microelectronics and 3D-printed soft polymers (Photo courtesy of Yongdeok Kim)
Image: The eBiobots are the first wireless bio-hybrid machines, combining biological tissue, microelectronics and 3D-printed soft polymers (Photo courtesy of Yongdeok Kim)

A team of researchers has developed remotely controlled miniature biological robots that could find potential applications in medicine, such as minimum invasive surgery or detection of cancer within the human body.

The hybrid “eBiobots” are the first to combine soft materials, living muscle and microelectronics, according to researchers at the University of Illinois Urbana-Champaign (Champaign, IL, USA), Northwestern University (Evanston, IL, USA) and collaborating institutions. They have described their centimeter-scale biological machines in the journal Science Robotics.

Researchers at the University of Illinois Urbana-Champaign had earlier developed biobots, which are small biological robots powered by mouse muscle tissue grown on a soft 3D-printed polymer skeleton. In 2012, the team had demonstrated walking biobots. In 2016, they had also demonstrated light-activated biobots which provided the researchers with some control. However, the inability to deliver the light pulses to the biobots outside of a lab setting limited their practical applications. This time, researchers at Northwestern University helped integrate tiny wireless microelectronics and battery-free micro-LEDs, allowing them to remotely control the eBiobots.

With the aim of providing freedom of movement to the biobots in order to make them suitable for practical applications, the researchers focused on eliminating bulky batteries and tethering wires. The eBiobots use a receiver coil to harvest power and provide a regulated output voltage to power the micro-LEDs. The researchers are able to send a wireless signal to the eBiobots that prompts the LEDs to pulse. The LEDs stimulate the light-sensitive engineered muscle to contract, moving the polymer legs so that the machines can “walk.” The micro-LEDs are so targeted in a way that they can activate specific portions of muscle, making the eBiobot turn in the desired direction.

Using computational modeling, the researchers optimized the eBiobot design and integrated the components for robustness, speed and maneuverability. The iterative design and additive 3D printing of the scaffolds enabled rapid cycles of experiments and improvement in performance, according to the researchers. The design offers potential for future integration of additional microelectronics, such as chemical and biological sensors, or 3D-printed scaffold parts for functions like pushing or transporting things that the biobots can encounter. The integration of electronic sensors or biological neurons could allow the eBiobots to sense and respond to biomarkers for disease, among other possibilities.

“Integrating microelectronics allows the merger of the biological world and the electronics world, both with many advantages of their own, to now produce these electronic biobots and machines that could be useful for many medical, sensing and environmental applications in the future,” said study co-leader Rashid Bashir, an Illinois professor of bioengineering and dean of the Grainger College of Engineering.

“In developing a first-ever hybrid bioelectronic robot, we are opening the door for a new paradigm of applications for health care innovation, such as in-situ biopsies and analysis, minimum invasive surgery or even cancer detection within the human body,” said co-first author Zhengwei Li, an assistant professor of biomedical engineering at the University of Houston.

Related Links:
University of Illinois Urbana-Champaign 
Northwestern University 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more